Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
There is no single Asia-Pacific CAR-T approval list or regional price. Approvals, availability and reimbursement are country-specific, and the available sources do not establish a complete, current inventory for every market. They do provide published price examples for China and Japan and a dated observation about India. Those figures are useful context, not 2026 quotes or estimates of what an individual patient will pay.
Why “approved in Asia-Pacific” is not one answer
A CAR-T therapy’s approval in one country does not establish approval in another. Nor does approval by itself mean a product is currently available at a local treatment center, covered by a payer, or affordable for a particular patient.
A 2025 regional review compares regulatory frameworks, pricing trends and reimbursement policies in Singapore, Japan, South Korea, China, India and Thailand. Its abstract does not list every currently approved product or give a current price for each country. The evidence summarized here therefore cannot answer “every therapy” for the whole region or confirm current 2026 approval status country by country.
Free tools Windows power users keep installed
One-click scans. No signup required.
To establish the answer for a specific patient, check that country’s regulator for the product and indication, then check local availability and the relevant insurer or public payer for coverage and patient cost-sharing. These are separate questions, not interchangeable meanings of “approved.”
#1 Best Overall
Published product-price examples
A 2024 article reports the following China-approved product examples and per-infusion prices. The values are publication-era figures; they should not be treated as current offers, payer-negotiated prices or a patient’s final bill.
| Jurisdiction | Product and brand | Approval date reported | Reported product price | What the figure establishes |
|---|---|---|---|---|
| China | Axicabtagene ciloleucel (Yikaida) | June 22, 2021 | RMB 1.2 million per infusion; the article’s approximate conversion was US$168,211 | Price reported in a 2024 article; current price and patient liability not established. |
| China | Relmacabtagene autoleucel (Carteyva) | September 1, 2021 | RMB 1.29 million per infusion; the article’s approximate conversion was US$180,827 | Price reported in a 2024 article; current price and patient liability not established. |
| China | Equecabtagene autoleucel (FUCASO) | June 30, 2023 | RMB 1.166 million per infusion; the article’s approximate conversion was US$163,445 | Price reported in a 2024 article; current price and patient liability not established. |
| Japan | Five CAR-T drugs; the review does not name them in the price finding summarized here | Not stated in the 2024 access review’s price finding | JPY 32,647,761 per drug, approximately US$242,000 at the review’s conversion | A 2024 review reports the same price for five drugs; it does not establish current 2026 prices or an individual’s final expense. |
The China article reports approval dates and prices for these examples, but the evidence available here does not supply their approved indications or patient groups. Do not use this table to decide clinical eligibility, compare clinical suitability, or infer that products are interchangeable. Confirm the current local label with the relevant regulator and treating team.
Rank #2
- Cancer Immunotherapy Principles and Practice
- ABIS BOOK
- Demos Medical Publishing
What the reported figures mean for patients
A product price is only one part of treatment cost
The EBMT/EHA CAR-T Cell Handbook describes a treatment episode as involving more than the cell product: preparation can include leukapheresis and lymphodepletion, followed by infusion, pre- and post-infusion management, and monitoring for side effects. The listed product price alone does not establish the total cost of care.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchCoverage changes the amount a patient pays
Insurance, public reimbursement, eligibility rules, reimbursement ceilings and negotiated terms can all affect out-of-pocket expense. A quoted price should not be presented as the amount every patient pays.
For Japan, the 2024 Asian access review describes the high-cost medical care reimbursement system, under which expenses above a limit are reimbursed later. The review does not determine an individual’s applicable limit, timing, eligibility or final liability. Patients need to confirm those details with their insurer or relevant payer.
China’s supplemental-coverage example is historical
The 2024 China article describes Shanghai’s Huimin Bao/Huhuibao scheme using 2022 terms: a RMB 129 annual premium, medical coverage up to RMB 3.1 million, and a RMB 500,000 ceiling for CAR-T products. These are historical scheme details, not verified current benefits. They do not show that a particular patient or product qualifies, or that a current policy will cover the full product price.
Rank #4
What is known about other markets
The 2025 regional review covers Singapore, South Korea, Thailand and India as well as China and Japan, but the available abstract does not enumerate current product approvals or local prices for those markets. No product-by-product approval or cost claim for Singapore, South Korea or Thailand can be established from that material alone.
The 2024 Asian access review said India had no approved commercial CAR-T products at that time. That is a dated observation, not confirmation of India’s status in 2026. Current approval and access would need to be checked against India’s regulator and payer information.
Best Value
How to find the answer for a specific country
- Check the regulator’s current product record. Confirm the brand or active product, approval status, date, and the exact indication and patient group in the local label.
- Ask the treating center about availability. Regulatory approval does not by itself confirm that a product is being offered at a particular hospital.
- Ask the payer what is covered. Confirm eligibility, prior authorization, reimbursement limits, patient cost-sharing and whether assistance or supplemental coverage applies.
- Request a treatment-episode estimate. Ask whether the estimate includes cell preparation, lymphodepletion, infusion, hospitalization or other management, and follow-up monitoring, rather than only the product.
- Confirm when and how reimbursement is paid. A benefit that reimburses costs after a threshold is reached may affect cash flow differently from a discount or direct payment to the provider.
Because product prices and coverage terms can change, use dated publications as historical reference points and obtain current terms from the relevant regulator, payer and treatment center before making financial decisions.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
